JP7651553B2 - ケメリン類似体を含む組成物とその使用方法 - Google Patents

ケメリン類似体を含む組成物とその使用方法 Download PDF

Info

Publication number
JP7651553B2
JP7651553B2 JP2022506697A JP2022506697A JP7651553B2 JP 7651553 B2 JP7651553 B2 JP 7651553B2 JP 2022506697 A JP2022506697 A JP 2022506697A JP 2022506697 A JP2022506697 A JP 2022506697A JP 7651553 B2 JP7651553 B2 JP 7651553B2
Authority
JP
Japan
Prior art keywords
acid
pain
peptide
tic
nle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543598A (ja
JP2022543598A5 (https=
Inventor
シャイルブハイ クンワー
ブイ．パティル ラージクマール
Original Assignee
オーケーワイオー ファーマ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーケーワイオー ファーマ リミティド filed Critical オーケーワイオー ファーマ リミティド
Publication of JP2022543598A publication Critical patent/JP2022543598A/ja
Publication of JP2022543598A5 publication Critical patent/JP2022543598A5/ja
Application granted granted Critical
Publication of JP7651553B2 publication Critical patent/JP7651553B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2022506697A 2019-08-01 2020-07-29 ケメリン類似体を含む組成物とその使用方法 Active JP7651553B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881725P 2019-08-01 2019-08-01
US62/881,725 2019-08-01
PCT/US2020/044045 WO2021021915A1 (en) 2019-08-01 2020-07-29 Compositions comprising chemerin analogs and methods of use

Publications (3)

Publication Number Publication Date
JP2022543598A JP2022543598A (ja) 2022-10-13
JP2022543598A5 JP2022543598A5 (https=) 2023-08-07
JP7651553B2 true JP7651553B2 (ja) 2025-03-26

Family

ID=72087242

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506697A Active JP7651553B2 (ja) 2019-08-01 2020-07-29 ケメリン類似体を含む組成物とその使用方法

Country Status (6)

Country Link
US (1) US12559523B2 (https=)
EP (2) EP4007635B1 (https=)
JP (1) JP7651553B2 (https=)
AU (1) AU2020321898B2 (https=)
CA (1) CA3149397A1 (https=)
WO (1) WO2021021915A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4522118A2 (en) * 2022-05-12 2025-03-19 Okyo Pharma Limited Chemerin-containing formulation for treating dry eye disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010229093A (ja) 2009-03-27 2010-10-14 Banyu Pharmaceut Co Ltd 新規ＣｈｅｍｅｒｉｎＲアゴニスト
WO2014168721A2 (en) 2013-04-12 2014-10-16 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
WO2019001459A1 (zh) 2017-06-27 2019-01-03 凯惠科技发展(上海)有限公司 一种肽类化合物、其应用及含其的组合物
JP2019507182A (ja) 2016-01-22 2019-03-14 タフツ メディカル センター インコーポレイテッド 炎症を処置するための化合物および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419658B2 (en) * 2001-07-09 2008-09-02 Euroscreen S.A. Isolated ligand of ChemerinR
US20090053831A1 (en) * 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20170039314A1 (en) * 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2013117581A1 (en) 2012-02-10 2013-08-15 Charite - Universitätsmedizin Berlin Metabolically stable variants of chemerin 9

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010229093A (ja) 2009-03-27 2010-10-14 Banyu Pharmaceut Co Ltd 新規ＣｈｅｍｅｒｉｎＲアゴニスト
WO2014168721A2 (en) 2013-04-12 2014-10-16 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
JP2019507182A (ja) 2016-01-22 2019-03-14 タフツ メディカル センター インコーポレイテッド 炎症を処置するための化合物および方法
WO2019001459A1 (zh) 2017-06-27 2019-01-03 凯惠科技发展(上海)有限公司 一种肽类化合物、其应用及含其的组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Development of a Membrane-anchored Chemerin Receptor Agonist as a Novel Modulator of Allergic Airway Inflammation and Neuropathic Pain，THE JOURNAL OF BIOLOGICAL CHEMISTRY，2014年，VOL. 289, NO. 19，pp. 13385-13396
Identification of a stable chemerin analog with potent activity toward ChemR23，Peptides，2009年，30，pp.1529-1538，doi:10.1016/j.peptides.2009.05.030

Also Published As

Publication number Publication date
WO2021021915A1 (en) 2021-02-04
EP4218927A2 (en) 2023-08-02
EP4007635B1 (en) 2024-06-19
CA3149397A1 (en) 2021-02-04
EP4007635A1 (en) 2022-06-08
JP2022543598A (ja) 2022-10-13
US20220267377A1 (en) 2022-08-25
EP4218927A3 (en) 2023-08-09
AU2020321898B2 (en) 2026-02-19
US12559523B2 (en) 2026-02-24
AU2020321898A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
JP7432028B2 (ja) 炎症を処置するための化合物および方法
WO2015138604A1 (en) Compositions and methods for treating eye infections and disease
EP3599245A1 (en) Il-17a binding polypeptides and medical uses thereof
JP7651553B2 (ja) ケメリン類似体を含む組成物とその使用方法
US20190241624A1 (en) Antimicrobial peptides and uses thereof
WO2018195491A1 (en) Compositions and methods for the treatment of amyotrophic lateral sclerosis
EP4007636B1 (en) Compositions comprising bovine adrenal medulla 8-22 (bam8-22) peptide analogs and methods of use
US12171858B2 (en) Peptide for treating sepsis derived from Rv2626c protein of Mycobacterium tuberculosis
HK40097419A (en) Compositions comprising chemerin analogs and methods of use
HK40075089B (en) Compositions comprising chemerin analogs and methods of use
HK40075089A (en) Compositions comprising chemerin analogs and methods of use
JP2025516630A (ja) ドライアイ疾患治療用製剤
US20230203107A1 (en) Peptide for treating sepsis derived from rv3364c protein of mycobacterium tuberculosis
HK40000831B (en) Compounds and methods for treating inflammation
HK40000831A (en) Compounds and methods for treating inflammation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250313

R150 Certificate of patent or registration of utility model

Ref document number: 7651553

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150